aiwiki.page
English
Health / Medicine & Treatment / immune-effector-cell-associated-neurotoxicity-syndrome

Immune Effector Cell-Associated Neurotoxicity Syndrome

Immune effector cell-associated neurotoxicity syndrome is an acute neurological complication of certain immune-based cancer treatments, characterized by cognitive changes, language impairment, altered consciousness, or seizures.

22 keywords7 linked fromWritten by AI
Central Nervous…CAR T-Cell Thera…Bispecific Antib…Cytokine Release…Cancer Immunothe…Acute Lymphoblas…LymphomaMultiple MyelomaImmune Eff…

Immune effector cell-associated neurotoxicity syndrome (ICANS) is a clinical syndrome affecting the central nervous system after treatments that activate or administer immune effector cells. It is most closely associated with chimeric antigen receptor T-cell therapy (CAR T-cell therapy), but also occurs with some bispecific antibodies that redirect T cells toward cancer cells. Manifestations range from impaired attention and difficulty finding words to profound impairment of consciousness, seizures, and, rarely, life-threatening cerebral swelling. ICANS is distinct from cytokine release syndrome (CRS), although the two frequently occur in the same treatment course.

Terminology and clinical setting

The term ICANS was standardized in the American Society for Transplantation and Cellular Therapy’s 2019 consensus framework for grading toxicities associated with immune effector cell therapies. It replaced several overlapping descriptions of treatment-related neurotoxicity and provided a common language for clinical care and research.

ICANS is particularly relevant to cancer immunotherapy for blood cancers, including acute lymphoblastic leukemia, lymphoma, and multiple myeloma. Its frequency and severity vary substantially between products, disease settings, and patient populations. An incidence reported for one treatment cannot be assumed to apply to another.

Not every neurological adverse event after an immune-based treatment is ICANS. Certain therapies are also associated with delayed movement disorders, cranial nerve abnormalities, or peripheral nerve complications that may have a different clinical course and mechanism.

Timing and clinical features

After CAR T-cell infusion, ICANS commonly develops within the first week, although onset may occur later. It can begin during CRS, follow its resolution, or occur without clinically apparent CRS. Timing with T-cell-engaging antibodies depends on the agent and treatment schedule.

Early manifestations can be subtle:

  • Reduced attention, slowed thinking, or disorientation.
  • Difficulty naming objects or following instructions.
  • Deterioration in handwriting or inability to write a meaningful sentence.
  • Word-finding difficulty or aphasia.
  • Tremor, agitation, or unusual sleepiness.

More severe disease can involve marked loss of language function, reduced responsiveness, seizures, focal motor weakness, or coma. Seizures may be nonconvulsive, producing altered awareness without conspicuous limb movements. Cerebral edema is uncommon but is among the most serious manifestations.

Headache—written here as headache—and other nonspecific symptoms may accompany treatment, but do not by themselves establish ICANS or determine its consensus severity grade.

Biological mechanisms

ICANS is understood as a consequence of immune activation and inflammatory injury affecting the brain’s vascular and supporting systems. Its mechanism is incompletely resolved and is unlikely to be identical across all therapies.

Activation of T cells and other immune cells produces cytokines and amplifies systemic inflammation. Activation of the vascular endothelium, which lines blood vessels, can increase vascular permeability and disturb the blood–brain barrier. These changes may allow circulating inflammatory mediators to affect the brain more readily and promote local inflammatory signaling.

Elevated inflammatory mediators have been detected in blood and cerebrospinal fluid during ICANS. These associations support an inflammatory mechanism, but no single mediator explains all cases. The presence of engineered T cells in cerebrospinal fluid also does not, by itself, establish the cause or severity of neurological injury.

Greater disease burden, stronger inflammatory responses, and more severe CRS have been associated with increased risk in some studies. Their predictive value varies by treatment and population; no single pretreatment characteristic reliably predicts an individual patient’s course.

Assessment and severity grading

ICANS is a clinical diagnosis based on the treatment context, neurological findings, their timing, and assessment for competing causes. No laboratory test or imaging finding independently confirms it.

The consensus grading system evaluates five domains:

  1. Cognitive function.
  2. Level of consciousness.
  3. Seizures.
  4. Motor findings.
  5. Raised intracranial pressure or cerebral edema.

The overall grade is determined by the most severe attributable finding, rather than an average across domains. Findings caused by sedating medication, metabolic disturbances, or another disease are not automatically attributed to ICANS.

The ICE assessment

For adults and developmentally suitable older children, the Immune Effector Cell-Associated Encephalopathy (ICE) assessment assigns up to 10 points:

Task Maximum points
Orientation to year, month, city, and hospital 4
Naming three objects 3
Following a simple command 1
Writing a standard sentence 1
Counting backward from 100 by tens 1

ICE scores contribute to grading but are not sufficient on their own:

Grade Cognitive and consciousness features
1 ICE score 7–9; spontaneous wakefulness
2 ICE score 3–6; awakening to voice
3 ICE score 0–2; awakening only to touch
4 Unarousable state, or requirement for vigorous or repeated tactile stimulation

An awake person with profound aphasia may score zero without being in a grade 4 state. Conversely, prolonged seizures, deep focal motor weakness, or diffuse cerebral edema may establish grade 4 disease independently of an interpretable ICE score. Rapidly resolving clinical seizures or certain electrographic seizures fall within grade 3 criteria; prolonged or repetitive seizures without recovery fall within grade 4 criteria.

Younger children require developmentally appropriate assessment, including the Cornell Assessment of Pediatric Delirium within the consensus framework.

Diagnostic evaluation and competing explanations

Serial neurological examinations help establish the trajectory of symptoms. Electroencephalography can identify nonconvulsive seizures and characterize abnormal brain activity. Magnetic resonance imaging or computed tomography may help investigate structural abnormalities, bleeding, or swelling, although imaging can be normal in clinically significant ICANS.

The differential diagnosis includes:

  • Infection of the central nervous system or systemic infection with encephalopathy.
  • Stroke or intracranial hemorrhage.
  • Electrolyte disturbances, low blood glucose, or organ dysfunction.
  • Medication effects.
  • Seizure-related changes.
  • Cancer involving the central nervous system.

Cerebrospinal fluid examination may help investigate infection or malignant involvement when clinically appropriate. Its inflammatory findings are not specific to ICANS. Blood inflammatory markers may accompany the syndrome, but no biomarker is sufficiently established to replace clinical assessment.

Clinical management

Management in specialist treatment settings depends on severity and includes repeated neurological assessment, supportive care, and treatment of seizures and other complications. Severe disease may require intensive care.

Corticosteroids are central to treatment of clinically significant ICANS in established management protocols. Choice, dose, and duration depend on severity, response, and the therapy involved. Antiseizure medicines are used for documented seizures; preventive use varies between protocols.

Tocilizumab, an antibody targeting the interleukin-6 receptor, is used for CRS but is not an established treatment for isolated ICANS. Improvement in systemic inflammation does not necessarily produce improvement in neurological symptoms. When CRS and ICANS coexist, the two toxicities are assessed and managed separately.

Additional anti-inflammatory approaches have been used for refractory cases. Their evidence base and place in treatment are less established than those of corticosteroids.

Outcomes and evidence limitations

Many episodes resolve over days to weeks, particularly when mild or moderate. Severe cases may involve prolonged hospitalization, neurological disability, or death. Persistent cognitive or neurological symptoms have been reported, but separating the effects of ICANS from prior cancer treatment, critical illness, and other causes can be difficult.

Comparisons across studies are limited by differences in therapies, patient populations, monitoring, grading systems, and management protocols. Earlier studies often used neurotoxicity definitions that are not directly interchangeable with current ICANS criteria. Long-term neurological outcomes and reliable prediction remain important areas of investigation.